Tania Papkovskaia, PhD

Senior Associate, Fountain Healthcare Partners – Board observer

Tania Papkovskaia qualified with a B.Sc. in Biochemistry from University College Dublin in 2009 and earned a PhD in Clinical Neuroscience from University College London, sponsored by Eisai Limited in collaboration with the Welcome Trust Consortium and the Institute of Neurology. In addition, she conducted postdoctoral research at the department of Oncology, University of Cambridge, investigating the role of cyclin-dependent kinase inhibitors in neuroblastoma.
In 2014, Tania joined the Healthcare team at the Gerson Lehrman Group, providing diligence support to global healthcare investors, coordinating business development efforts and product campaigns across pharmaceutical, biotechnology and medical device segments. In 2017, she took over the European Healthcare team, a $4.5 million division, with responsibility spanning revenue, commercial strategy, operational performance, training and development.

Management team

Scientific Advisor

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors​

Scientific Advisory Board

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow